WO2019196620A1 - 喹唑啉类化合物与阿瓦斯汀在制备防止疾病的联合用药物中的用途 - Google Patents

喹唑啉类化合物与阿瓦斯汀在制备防止疾病的联合用药物中的用途 Download PDF

Info

Publication number
WO2019196620A1
WO2019196620A1 PCT/CN2019/079044 CN2019079044W WO2019196620A1 WO 2019196620 A1 WO2019196620 A1 WO 2019196620A1 CN 2019079044 W CN2019079044 W CN 2019079044W WO 2019196620 A1 WO2019196620 A1 WO 2019196620A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
avastin
disease
quinazoline
use according
Prior art date
Application number
PCT/CN2019/079044
Other languages
English (en)
French (fr)
Inventor
钟卫
张金强
Original Assignee
威尚（上海）生物医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810422165.6A external-priority patent/CN110354261B/zh
Application filed by 威尚（上海）生物医药有限公司 filed Critical 威尚（上海）生物医药有限公司
Publication of WO2019196620A1 publication Critical patent/WO2019196620A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to the use of a quinazoline compound and Avastin in the preparation of a combined disease prevention disease, and belongs to the technical field of biomedicine.
  • a quinazoline derivative having a cross-blood-brain barrier having a cross-blood-brain barrier, the molecular formula C 23 H 21 F 3 N 4 O 2 , the chemical name (R)-6-[(3,3-difluoro-1-methylpiperidine-4) -yl)oxy]-nitro-(3-ethynyl-2-fluorophenyl)-7-methoxyquinazolin-4-amine (I)
  • R -6-[(3,3-difluoro-1-methylpiperidine-4) -yl)oxy]-nitro-(3-ethynyl-2-fluorophenyl)-7-methoxyquinazolin-4-amine (I)
  • I is a molecularly targeted antitumor drug that has Highly selective epidermal growth factor receptor EGFR tyrosine kinase inhibitor for the treatment of non-small cell lung cancer brain metastases, meningeal metastasis, head and neck squamous
  • Chinese Patent No. 201610982608.6 describes a preparation method and application of the above quinazoline derivative (I) (Formula C 23 H 21 F 3 N 4 O 2 ).
  • a single drug having a metered-dependent pharmacological effect can advantageously inhibit the growth of cancer cells at high doses, but may produce greater toxic side effects. Therefore, a pharmaceutical composition capable of producing a synergistic effect is developed, the efficacy of a single drug is improved, the toxic side effect of the second therapeutic agent or the compound (I) of the present invention is minimized, the efficacy is improved, and the convenience of administration or use is improved. And/or reducing the overall cost of a compound preparation or formulation is very useful and significant.
  • the present invention provides the use of a quinazoline compound and Avastin in the preparation of a combination disease preventing disease.
  • the quinazoline compound comprises at least one of a quinazoline derivative of the formula I and a salt, a prodrug, a prodrug salt, a solvate, a hydrate and a polymorph thereof.
  • the quinoline compound comprises a hydrochloride, a sulfate, a maleate, a succinate, an adipate, a glycolate, a malate, a fumarate of a quinazoline derivative. , besylate, benzoate, horse urate and oxalate and solvates, hydrates, polymorphs.
  • the disease comprises a central nervous system metastasis of a disease including cancer, proliferative disease, neurological disease or cancer.
  • the cancer comprises non-small cell lung cancer, glioma, brain stem tumor, gastric cancer, colorectal cancer, head and neck squamous cell carcinoma, lung squamous cell carcinoma and pancreatic cancer; and the central nervous system metastasis of the cancer includes non-small Cellular lung cancer meningeal metastasis, non-small cell lung cancer brain metastasis.
  • the Avastin is in an injectable form.
  • the quinazoline compound is in an oral dosage form, a suppository form or an injectable dosage form.
  • the quinazoline compound and Avastin are used in a dose ratio of 1:10 to 1:1.
  • the present invention has the following beneficial effects:
  • the quinazoline derivative (I) of the present invention, and a pharmaceutical salt thereof and a combination of Avastin have an unexpected synergistic effect and have a better therapeutic effect than a single drug, such as cancer, cancer brain metastasis, Cancer meningeal metastasis, brain cancer and neurological diseases;
  • composition of the quinazoline derivative (I) of the present invention, a pharmaceutical salt thereof and Avastin can prolong the time required for cancer cells to produce resistance and prolong the progression-free survival of the disease.
  • Figure 1 is a pharmacodynamic experiment of a combination of subcutaneous models of PC-9 cancer cells in mice.
  • the diameter of the mouse xenografts was measured with a vernier caliper, and the animals were randomly divided into groups after the tumors were grown to 150-200 mm 3 .
  • the antitumor effect of the test drug was dynamically observed using a method of measuring the tumor diameter. The measurement of the diameter of the tumor is once every 3 days, and the weight of the mouse is also weighed for each measurement.
  • the grouping and administration methods are as follows:
  • the Avastin group was administered intraperitoneally, 5 mg/kg, twice a week.
  • the quinazoline derivative (I) of the present invention is administered by intragastric administration at a dose of 1 mg/kg twice a day.
  • Avastin-the quinazoline derivative (I) combination group according to the present invention Avastin is administered intraperitoneally, 5 mg/kg, twice a week, the quinazoline derivative of the present invention (I) Administration by intragastric administration at a dose of 1 mg/kg administered twice a day.
  • the negative control group was injected with the same amount of normal saline twice a day.
  • Tumor volume calculation formula: TV 0.52 ⁇ a ⁇ b 2 , where a and b represent the length and width, respectively.
  • the relative tumor volume was calculated based on the measured results.
  • the drug was administered on the eighth day of implantation of the tumor cells, and the second group of quinazoline derivatives (I) was administered as a single drug, 1 mg/ Kg, oral, twice a day and the third group of Avastin, single drug, intraperitoneal administration, twice a week compared to the first group of control group (without drug group) showed good inhibition of tumor growth, statistically significant The efficacy of the drug.
  • the fourth group of the pharmaceutical compositions of the present invention unexpectedly showed a synergistic effect, and the second group and the third group of single drug groups improved the efficacy against a single drug. And have statistically significant differences in efficacy.
  • the contrast blank group showed a good inhibition of tumor growth with statistically significant efficacy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供了一种喹唑啉类化合物与阿瓦斯汀在制备防止疾病的联合用药物中的用途，所述喹唑啉类化合物包括式I所示的喹唑啉衍生物及其盐、前药、前药盐、溶剂合物、水合物和多晶型物中的至少一种， (I) 与现有技术相比，本发明具有如下的有益效果：1、本发明所述的喹唑啉衍生物(I)及其药学盐和阿瓦斯汀的组合物具有预料之外的协同效应，比单一药物具有更好的疗效，例如癌症、癌症脑转移，癌症脑膜转移，脑癌和神经中枢疾病等；2、本发明所述的喹唑啉衍生物(I)及其药学盐和阿瓦斯汀的组合物可延长癌细胞产生耐药所需时间，延长疾病无进展生存期。

Description

喹唑啉类化合物与阿瓦斯汀在制备防止疾病的联合用药物中的用途 技术领域
本发明涉及一种喹唑啉类化合物与阿瓦斯汀在制备防止疾病的联合用药物中的用途，属于生物医药技术领域。
背景技术
具有穿过血脑屏障的喹唑啉衍生物，分子式C 23H 21F 3N 4O 2，化学名(R)-6-[(3,3-二氟-1-甲基哌啶-4-基)氧基]-氮-(3-乙炔基-2-氟苯基)-7-甲氧基喹唑啉-4-胺(I)，是一种分子靶向抗肿瘤药物，是具有高选择性的表皮生长因子受体EGFR酪氨酸激酶抑制剂，可用于治疗非小细胞肺癌脑转移，脑膜转移，头颈部鳞状细胞癌，鳞状细胞癌，脑干肿瘤，原发性脑癌，脑胶质瘤或其他癌症等。中国专利201610982608.6描述了上述喹唑啉衍生物(I)(分子式C 23H 21F 3N 4O 2)的制备方法及应用。如本领域技术人员所知，具有计量依赖性药效的单一药物在高剂量可有利的抑制癌细胞的生长，但是可能会产生更大的毒副作用。因此，研发能产生协同效应的药物组合物，提高单一药物的疗效，使第二治疗剂或本发明所述的化合物(I)的毒副作用最小化，改善功效，改善给药或使用的方便性，和/或降低化合物制品或制剂的总体花费是非常有用的，具有重要意义。
发明内容
针对现有技术中的缺陷，本发明的目的是提供一种含有喹唑啉衍生物和阿瓦斯汀的药物组合物。
本发明是通过以下技术方案实现的：
本发明提供了喹唑啉类化合物与阿瓦斯汀在制备防止疾病的联合用药物中的用途。
作为优选方案，所述喹唑啉类化合物包括式I所示的喹唑啉衍生物及其盐、前药、前药盐、溶剂合物、水合物和多晶型物中的至少一种，
Figure PCTCN2019079044-appb-000001
作为优选方案，所述喹啉类化合物包括喹唑啉衍生物的盐酸盐、硫酸盐、马来酸盐、琥珀酸盐、己二酸盐、乙醇酸盐、苹果酸盐、富马酸盐、苯磺酸盐、苯甲酸盐，马尿酸盐及草酸盐及溶剂合物、水合物、多晶型物。
作为优选方案，所述疾病包括疾病包括癌症、增殖疾病、神经中枢疾病或癌症的中枢神经转移疾病。
作为优选方案，所述癌症包括非小细胞肺癌、脑胶质瘤、脑干肿瘤、胃癌、结直肠癌、头颈鳞癌、肺鳞癌和胰腺癌；所述癌症的中枢神经转移疾病包括非小细胞肺癌脑膜转移、非小细胞肺癌脑转移。
作为优选方案，所述阿瓦斯汀采用注射剂型。
作为优选方案，所述喹唑啉类化合物采用口服剂型、栓剂型或注射剂型。
作为优选方案，所述喹唑啉类化合物与阿瓦斯汀的使用剂量比为1：10～1：1。
与现有技术相比，本发明具有如下的有益效果：
1、本发明所述的喹唑啉衍生物(I)及其药学盐和阿瓦斯汀的组合物具有预料之外的协同效应，比单一药物具有更好的疗效，例如癌症、癌症脑转移，癌症脑膜转移，脑癌和神经中枢疾病等；
2、本发明所述的喹唑啉衍生物(I)及其药学盐和阿瓦斯汀的组合物可延长癌细胞产生耐药所需时间，延长疾病无进展生存期。
附图说明
通过阅读参照以下附图对非限制性实施例所作的详细描述，本发明的其它特征、目的和优点将会变得更明显：
图1为在PC-9癌细胞小鼠皮下模型联合用药的药效实验。
具体实施方式
下面结合具体实施例对本发明进行详细说明。以下实施例将有助于本领域的技术人 员进一步理解本发明，但不以任何形式限制本发明。应当指出的是，对本领域的普通技术人员来说，在不脱离本发明构思的前提下，还可以做出若干变形和改进。这些都属于本发明的保护范围。
实施例1
阿瓦斯汀-本发明所述的喹唑啉衍生物(I)联合对非小细胞肺癌PC-9小鼠异种移植肿瘤生长的抑制作用
取对数生长期的非小细胞肺癌PC-9癌细胞(5x 10 6)，在0.1ml of RPMI-1640 and Matrigel(BD,cat.NO.356234)(1:1 ratio)的细胞悬液，接种于小鼠右翼皮下。8天后用游标卡尺测量小鼠移植瘤直径，待肿瘤生长至150-200mm 3后动物随机分组。使用测量瘤径的方法，动态观察被试药物的抗肿瘤效果。肿瘤直径的测量次数为每3天1次，每次测量同时还需称量鼠重。分组及给药方式如下：
阿瓦斯汀组采用腹腔注射，5mg/kg，每周给药2次。本发明所述的喹唑啉衍生物(I)组采用灌胃，给药剂量为1mg/kg，每天给药2次。阿瓦斯汀-本发明所述的喹唑啉衍生物(I)联合给药组，阿瓦斯汀采用腹腔注射，5mg/kg，每周给药2次，本发明所述的喹唑啉衍生物(I)采用灌胃，给药剂量为1mg/kg，每天给药2次。阴性对照组注射等量生理盐水，每天2次。肿瘤体积计算公式：TV＝0.52×a×b 2，其中a、b分别表示长宽。根据测量的结果计算出相对肿瘤体积。抗肿瘤活性的评价指标为相对肿瘤增殖率T/C(％)，计算公式：T/C(％)＝TRTV/CRTV×100％，TRTV：治疗组RTV；CRTV：阴性对照组RTV。
实施例2
PC-9肿瘤细胞小鼠皮下动物模型药效
如图1所示，在PC-9肿瘤细胞小鼠皮下动物模型药效实验中，在种植肿瘤细胞第八天开始给药，第二组喹唑啉衍生物(I)单药，1毫克/公斤，口服，一日两次和第三组阿瓦斯汀，单药，腹腔给药，一周两次对比第一组对照组(不含药物组)均显示肿瘤增长的良好抑制，具有统计学意义的药效。
Figure PCTCN2019079044-appb-000002
本发明所述药物组合物第四组(喹唑啉衍生物(I)和阿瓦斯汀组合物)出人意料显示协同效应，对比第二组和第三组单药组提高了对单一药物的药效，并具有统计学意义的药效差异。对比空白组显示肿瘤增长的良好抑制，具有统计学意义的药效。
以上对本发明的具体实施例进行了描述。需要理解的是，本发明并不局限于上述特定实施方式，本领域技术人员可以在权利要求的范围内做出各种变形或修改，这并不影响本发明的实质内容。

Claims (8)

  1. 喹唑啉类化合物与阿瓦斯汀在制备防止疾病的联合用药物中的用途。
  2. 如权利要求1所述的用途，其特征在于，所述喹唑啉类化合物包括式I所示的喹唑啉衍生物及其盐、前药、前药盐、溶剂合物、水合物和多晶型物中的至少一种，
    Figure PCTCN2019079044-appb-100001
  3. 如权利要求2所述的用途，其特征在于，所述喹啉类化合物包括喹唑啉衍生物的盐酸盐、硫酸盐、马来酸盐、琥珀酸盐、己二酸盐、乙醇酸盐、苹果酸盐、富马酸盐、苯磺酸盐、苯甲酸盐、马尿酸盐及草酸盐及溶剂合物、水合物、多晶型物。
  4. 如权利要求1所述的用途，其特征在于，所述疾病包括疾病包括癌症、增殖疾病、神经中枢疾病或癌症的中枢神经转移疾病。
  5. 如权利要求3所述的用途，其特征在于，所述癌症包括非小细胞肺癌、脑胶质瘤、脑干肿瘤、胃癌、结直肠癌、头颈鳞癌、肺鳞癌和胰腺癌；所述癌症的中枢神经转移疾病包括非小细胞肺癌脑膜转移、非小细胞肺癌脑转移。
  6. 如权利要求1所述的用途，其特征在于，所述阿瓦斯汀采用注射剂型。
  7. 如权利要求1所述的用途，其特征在于，所述喹唑啉类化合物采用口服剂型、栓剂型或注射剂型。
  8. 如权利要求1中任意一项所述的用途，其特征在于，所述喹唑啉类化合物与阿瓦斯汀的使用剂量比为1：10～1：1。
PCT/CN2019/079044 2018-04-09 2019-03-21 喹唑啉类化合物与阿瓦斯汀在制备防止疾病的联合用药物中的用途 WO2019196620A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201810312153 2018-04-09
CN201810312153.8 2018-04-09
CN201810422165.6 2018-05-04
CN201810422165.6A CN110354261B (zh) 2018-04-09 2018-05-04 喹唑啉类化合物与阿瓦斯汀在制备防止疾病的联合用药物中的用途

Publications (1)

Publication Number Publication Date
WO2019196620A1 true WO2019196620A1 (zh) 2019-10-17

Family

ID=68163914

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/079044 WO2019196620A1 (zh) 2018-04-09 2019-03-21 喹唑啉类化合物与阿瓦斯汀在制备防止疾病的联合用药物中的用途

Country Status (1)

Country Link
WO (1) WO2019196620A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102458410A (zh) * 2009-04-20 2012-05-16 吉联亚·卡利斯托加有限责任公司 治疗实体瘤的方法
CN108069946A (zh) * 2016-11-08 2018-05-25 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的取代的喹唑啉化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102458410A (zh) * 2009-04-20 2012-05-16 吉联亚·卡利斯托加有限责任公司 治疗实体瘤的方法
CN108069946A (zh) * 2016-11-08 2018-05-25 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的取代的喹唑啉化合物

Similar Documents

Publication Publication Date Title
CA3092753C (en) Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab
US20050026933A1 (en) Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
US20140378409A1 (en) Effect potentiator for antitumor agents
JP2017537126A5 (zh)
KR101848131B1 (ko) 저용량 이리노테칸염산염 수화물을 함유하는 항종양제
US20190290652A1 (en) Method for treatment of solid malignancies including advanced or metastatic solid malignancies
PT1446124E (pt) Terapia de combinação compreendendo zd6474 e um taxano
TW202133856A (zh) 涉及二芳基巨環化合物之組合療法
FI3463345T3 (fi) Farmaseuttisia yhdistelmiä
TW201914592A (zh) 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途
WO2021018310A1 (zh) 用于治疗非小细胞肺癌的氨基吡啶衍生物
CN110354261B (zh) 喹唑啉类化合物与阿瓦斯汀在制备防止疾病的联合用药物中的用途
WO2019196620A1 (zh) 喹唑啉类化合物与阿瓦斯汀在制备防止疾病的联合用药物中的用途
US20220062294A1 (en) Pharmaceutical compositions of tetracyclic quinolone analogs and their salts
KR20150136073A (ko) 이리노테칸염산염 수화물을 함유하는 항종양제
TW201306833A (zh) 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合
BRPI0717998A2 (pt) Método para administrar um composto antitumor.
JP2014034531A (ja) Ｈｓｐ９０阻害剤とゲムシタビンの組み合わせ
TWI813694B (zh) 抗腫瘤劑及腫瘤治療方法
WO2023011415A1 (zh) Egfr抑制剂的药物组合及其应用
WO2024088192A1 (en) An aurora a inhibitor for use in treatments of cancers
CN107137406B (zh) 一种Hedgehog信号通路抑制剂在制备治疗EGFR过度表达的癌症的药物中的用途
CN118059249A (zh) 喹唑啉类化合物与三代egfr抑制剂在治疗非小细胞肺癌的联合用药物中的用途
TWI307628B (en) Use of zd0473 in combination with a non-platinum based anti-cancer agent
JP2014034534A (ja) ＨＳＰ９０阻害剤とｍＴＯＲ阻害剤の組み合わせ

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19786186

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 12.02.2021)

122 Ep: pct application non-entry in european phase

Ref document number: 19786186

Country of ref document: EP

Kind code of ref document: A1